Trial: 201808122

Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus

Phase

III

Principal Investigator

Trikalinos, Nikolaos

Disease Site

Lung; Pancreas

Learn more about this study at: clinicaltrials.gov